Neuromodulation industry veteran joins company to lead commercial efforts
Boston, Massachusetts and Toronto, Ontario – September 23, 2019 – EBT Medical, Inc. (“EBT”) a venture-backed startup developing disruptive neuromodulation therapies for pelvic health disorders, today announced that Ken Mariash Jr. has joined the company as Vice President of Marketing to head commercial efforts.
“Ken brings an incredible breadth & depth of experience in building a neuromodulation business including experience with overall strategy, pelvic health, product development, and commercial operations perspectives to EBT,” said Keith R. Carlton, CEO of EBT. “He’s a perfect fit for this role and we are incredibly happy to have him on board.”
“I couldn’t be more excited to join the team at such a pivotal moment,” said Mariash. “Having evaluated hundreds of startups from the corporate development side, what excited me about coming aboard EBT was the enormous potential for its highly differentiated technology to address significant unmet needs and bring relief to a much wider audience of silent sufferers.”
Mariash has nearly 20 years’ experience in marketing, leading, and growing new businesses. He started his career in management consulting at Charles River Associates, and then joined CSL (Australia’s largest biotech), followed by Baxter BioScience (now Shire/Takeda), and Boston Scientific– with leadership roles in marketing, strategy, and corporate development. He was most recently the franchise lead for Boston Scientific’s Cosman radiofrequency ablation business, which he helped acquire. He also led Strategy for Boston Scientific’s ~$1B Neuromodulation division for 8 years, and held leadership roles overseeing development of Class II & III devices, digital strategy, business planning, and M&A assessments. Ken has degrees in Business Economics and Biochemistry from Brown University.
Mariash is expected to oversee all commercial aspects of EBT’s neuromodulation therapy development, business planning, and proposed launch in overactive bladder (OAB), EBT’s first planned targeted indication. He is also expected to drive future expansion efforts into multiple additional indications and follow-on devices. Given his background in strategy and business development, he is expected to also assist in EBT’s corporate development and fundraising efforts. “Ken brings an incredible breadth & depth of experience in building a neuromodulation business including experience with overall strategy, pelvic health, product development, and commercial operations perspectives to EBT,” said Keith R. Carlton, CEO of EBT. “He’s a perfect fit for this role and we are incredibly happy to have him on board.”
About EBT Medical
EBT Medical was founded in 2014 based on scientific discoveries made at the University of Toronto with a mission to develop novel neuromodulation technologies that restore control, dignity and independence to those silently suffering from pelvic floor disorders. EBT’s first product is a clinical-grade, noninvasive neurostimulator and associated ecosystem for overactive bladder (OAB). EBT has a significant patent estate around multiple neuromodulation technologies including issued patents on the Saphenous nerve for all pelvic health indications. EBT’s management team and world-class advisory board have decades of relevant experience in pelvic health, neuromodulation, and consumer health. Learn more about EBT Medical at www.ebtmedical.com
MassChallenge is a global network of zero-equity startup accelerators. Headquartered in the United States with locations in Boston, Israel, Mexico, Rhode Island, Switzerland, and Texas, MassChallenge is committed to strengthening the global innovation ecosystem by supporting high-potential early stage startups across all industries, from anywhere in the world. To date, more than 1,500 MassChallenge alumni have raised more than $3 billion in funding, generated over $2 billion in revenue, and created over 80,000 total jobs. Learn more about MassChallenge at masschallenge.org
About Overactive Bladder and Neuromodulation
Overactive bladder is a disabling syndrome affecting nearly 550M worldwide1. It is characterized by frequent, sudden, uncontrollable urges to void, often followed by incontinence episodes that are embarrassing and significantly impede activities of daily living. The major symptom of OAB, Urge Urinary Incontinence (UUI), is thought to be caused by over-signaling to & from the bladder and the pontine micturition center located in the brain stem. Over 50%2 of those with OAB remain undiagnosed and silently suffer, with marked increases in depression, anxiety, sleeplessness due to nocturia (waking to void), and social isolation. The economic impact of OAB in the United States was estimated at $76B including direct costs and indirect costs such as increased urinary tract infections, falls from running to the bathroom, and absenteeism3. Neuromodulation has been an established therapy for UUI since it was first approved in 1997.
Keith R Carlton
Chief Executive Officer
Certain information set forth in this press release contains “forward-looking information”, including “future oriented financial information” and “financial outlook”, under applicable securities laws (collectively referred to herein as forward-looking statements). Except for statements of historical fact, information contained herein constitutes forward-looking statements. Forward-looking statements are provided to allow potential investors the opportunity to understand management’s beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment.
These statements are not guarantees of future performance and undue reliance should not be placed on them. Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or result expressed or implied by such forward-looking statements.
Although forward-looking statements contained in this presentation are based upon what management of EBT Medical believes are reasonable assumptions, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. EBT Medical undertakes no obligation to update forward-looking statements if circumstances or management’s estimates or opinions should change except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements.
1 546M affected individuals in 2018. Filipetto et al.: The patient perspective on overactive bladder: a mixed-methods needs assessment. BMC Family Practice 2014 15:96.
3 $76B in 2015. J Manag Care Pharm. 2014 Feb;20(2):130-40. “Economic burden of urgency urinary incontinence in the United States: a systematic review.”